Skip to main content
Compare/Z08 vs Z51

Z08 vs Z51

Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm) compared with Z51 (Encounter for other aftercare and medical care), from the official CMS tabular data. Do not report these codes together: the official tabular list marks them Excludes1.

Can these codes be reported together?

No — do not report together. Z08 carries an Excludes1 note covering Z51: “aftercare following medical care (Z43-Z49, Z51)”

Sole exception: when the two conditions are documented as unrelated to each other (ICD-10-CM Official Guidelines, Section I.A.12.a).

No — do not report together. Z51 carries an Excludes1 note covering Z08: “follow-up examination after treatment (Z08-Z09)”

Sole exception: when the two conditions are documented as unrelated to each other (ICD-10-CM Official Guidelines, Section I.A.12.a).

Yes, when both are documented. Z51 carries an Excludes2 note covering Z08: “follow-up examination for medical surveillance after treatment (Z08-Z09)”

Excludes2 marks distinct conditions — both may be reported when both are documented.

Side by side

Z08Encounter for follow-up examination after completed treatment for malignant neoplasmZ51Encounter for other aftercare and medical care
Billing statusBillableNon-billable header

Report instead: Z51.0, Z51.11, Z51.12, Z51.5, Z51.6

ClassificationZ00-Z99 — Factors Influencing Health Status and Contact with Health Services (Z00-Z99)Z00-Z99 — Factors Influencing Health Status and Contact with Health Services (Z00-Z99)
DefinitionEncounter for follow-up examination after completed treatment for malignant neoplasm is a billable ICD-10-CM diagnosis code (Z08).Encounter for other aftercare and medical care is a non-billable ICD-10-CM category code (Z51).
Includes
Medical surveillance following completed treatment
Use additional code
code to identify any acquired absence of organs (Z90.-)
code to identify the personal history of malignant neoplasm (Z85.-)

Derived from the official CMS ICD-10-CM tabular data (FY2026). Not billing advice; verify sequencing rules for the encounter. All data sources